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CSF biomarkersIn the current study, we have evaluated the performance of magnetic resonance (MR) T1rho (T1ρ) imaging and
CSF biomarkers (T-tau, P-tau and Aβ-42) in characterization of Alzheimer3s disease (AD) patients frommild cog-
nitive impairment (MCI) and control subjects. With informed consent, AD (n= 27), MCI (n= 17) and control
(n= 17) subjects underwent a standardized clinical assessment and brain MRI on a 1.5-T clinical-scanner. T1ρ
images were obtained at four different spin-lock pulse duration (10, 20, 30 and 40ms). T1ρmapswere generated
by pixel-wise ﬁtting of signal intensity as a function of the spin-lock pulse duration. T1ρ values from gray matter
(GM) and white matter (WM) of medial temporal lobe were calculated. The binary logistic regression using T1ρ
and CSF biomarkers as variables was performed to classify each group. T1ρwas able to predict 77.3% controls and
40.0%MCI while CSF biomarkers predicted 81.8% controls and 46.7%MCI. T1ρ and CSF biomarkers in combination
predicted 86.4% controls and 66.7% MCI. When comparing controls with AD, T1ρ predicted 68.2% controls and
73.9% AD, while CSF biomarkers predicted 77.3% controls and 78.3% for AD. Combination of T1ρ and CSF bio-
markers improved the prediction rate to 81.8% for controls and 82.6% for AD. Similarly, on comparing MCI with
AD, T1ρ predicted 35.3% MCI and 81.9% AD, whereas CSF biomarkers predicted 53.3% MCI and 83.0% AD. Collec-
tively CSF biomarkers and T1ρwere able to predict 59.3% MCI and 84.6% AD. On receiver operating characteristic
analysis T1ρ showed higher sensitivity while CSF biomarkers showed greater speciﬁcity in delineating MCI and
AD from controls. No signiﬁcant correlation between T1ρ and CSF biomarkers, between T1ρ and age, and between
CSF biomarkers and agewas observed. The combined use of T1ρ and CSF biomarkers have promise to improve the
early and speciﬁc diagnosis of AD. Furthermore, disease progression formMCI to ADmight be easily tracked using
these two parameters in combination.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer3s is a progressive disease, where dementia symptoms
gradually worsen over a number of years, and it accounts for 50–80%pinal ﬂuid;MRI, magnetic reso-
, total tau; Aβ1-42, amyloid beta
itive impairment;MMSE,Mini-
time; TSL, total spin lock; FOV,
isition gradient-echo; TI, inver-
ial temporal lobe; ROC, receiver
dical and Research Center, P.O.
4404 2001.
. This is an open access article underof dementia cases. Alzheimer3s disease (AD) is estimated to affect ~5.2
million Americans— a number expected to swell to as many as 16 mil-
lion by 2050. Efforts are in progress to ﬁnd better ways to treat the dis-
ease, delay its onset, and prevent it from developing. Many tools are
used to look for signs of AD, including a battery of cognitive and behav-
ioral tests (Koppel et al., 2012; Cummings, 2000; Harwood et al., 2000),
cerebrospinal ﬂuid (CSF) analysis (Hansson et al., 2006; Mattsson et al.,
2009), magnetic resonance imaging (MRI) (Fayed et al., 2012; Frisoni
et al., 2010; Chincarini et al., 2011) and positron emission tomography
(PET) scans (Pearson and Colby, 2013; Zhang et al., 2012; Kadir et al.,
2012). Imaging techniques (MRI and PET) and CSF studies have been
pointed as candidates for the diagnostic biomarkers of AD.
It has been found that the CSFmeasures of total tau (T-tau) and am-
yloid beta (Aβ1-42) levels are individually sensitive though but withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Quantitative values of T1ρ relaxation times and CSF biomarkers from control, MCI and AD
subjects.
Group T1ρ (ms)
(mean ± SE)
CSF biomarkers (pg/mL)
(mean ± SE)
Gray
matter
White
matter
Luminex
T-Tau
Luminex
P-Tau
Luminex
Aβ1-42
Control 86.8 ± 1.8 80.3 ± 2.1 56.9 ± 7.0 26.1 ± 3.6 230.4 ± 11.1
MCI 91.9 ± 1.2 85.2 ± 1.4 74.0 ± 12.2 30.6 ± 5.1 188.3 ± 16.0
AD 92.3 ± 1.0 88.7 ± 1.9 103.3 ± 10.8 39.0 ± 4.9 144.9 ± 10.4
ms=millisecond; SE= standard error; CSF= cerebrospinal ﬂuid; pg= picogram; ml=
milliliter; MCI = mild cognitive impairment; AD= Alzheimer3s disease.
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2004). Moreover, the CSF Aβ1-42 levels are not easily interpreted be-
cause CSF Aβ1-42 is not exclusively brain derived and also its produc-
tion and clearance are not well characterized. A number of studies
have suggested that CSF markers in combination with neuroimaging
and neuropsychological tools add to the accuracy of AD diagnosis
(Richard et al., 2013; Schuff et al., 2009; Vemuri et al., 2010).
Out of various medical imaging techniques, MRI is the most widely
accepted technique to detect the pathological changes in-vivo based
on the tissue T2 and T1 contrast relaxation properties. However, to
date none of the MRI methods has proven to be an accurate in-vivo
marker for early diagnosis of AD. Recently, a new MRI technique has
been introduced i.e T1rho (T1ρ), the spin lattice relaxation time constant
in the rotating frame, which determines the decay of transfer magneti-
zation in presence of “spin-lock” radio-frequency ﬁeld (Borthakur et al.,
2004, 2006b; Wheaton et al., 2005). In biological tissues, T1ρ may have
contribution from several molecular interactions. It is also possible
that more than one interaction may contribute to the T1ρ signal at a
time; however, their relative contributionsmay differ. Such interactions
include chemical exchange, dipolar interaction, and J-coupling. T1ρMRI
has capability to probe the protein contents in various tissues such as
brain, blood and cartilage.
T1ρMRI has been previously used tomeasure the T1ρ relaxation time
in the normal human brain, and showed higher range of values com-
pared to the T2 relaxation time (Borthakur et al., 2004). Earlier, T1ρ has
been used to delineate brain tumors (Aronen et al., 1999), characterize
breast cancer tissue (Li et al., 2011), and monitor the level of cartilage
degeneration (Regatte et al., 2004; Witschey et al., 2010). Borthakur
et al. have shown the feasibility of T1ρ imaging in evaluating the plaques
burden in amousemodel of AD (Borthakur et al., 2006a). Previous stud-
ies have shown higher T1ρ value in the medial temporal lobe (MTL) of
AD compared to those of mild cognitive impairment (MCI) and control
(Haris et al., 2011; Borthakur et al., 2008).
In the current study, we aim to evaluate the performance of T1ρ and
CSF biomarkers in characterization of AD patients fromMCI and control
subjects. In addition,we also assess any correlation between T1ρ and CSF
biomarkers.Fig. 1. T1rho (T1ρ) contrast frommedial temporal lobe overlaid on anatomic ﬂuid attenuated T
disease (AD, C) patients. A progressive increase in T1ρ contrast in medial temporal lobe (MTL)2. Materials and methods
2.1. Participants
Institutional Review Board of the University of Pennsylvania ap-
proved the current study protocol. In this study, we have included 27
AD patients (mean age ± SD = 76.8 ± 9.1 years), 17 MCI patients
(mean age ± SD = 71.93 ± 8.7 years), and 17 age-matched control
subjects (mean age ± SD = 70.2 ± 9.4 years). A standardized clinical
assessment including medical history, physical and neurological exam-
ination, psychometric evaluation, and brain MRI was performed in all
patients. The general cognitive function in each patient was assessed
using Mini-Mental State Examination (MMSE) score. Diagnoses was
made by a team consisting of neurologist, neuropsychologist, and psy-
chiatrist who performed extensive behavioral, neuropsychological,
and neuroimaging assessments. Diagnoses of MCI was made according
to the Petersen criteria for MCI (Petersen et al., 2001), while the AD pa-
tients were diagnosed according to the National Institute of Neurologi-
cal and Communicative Diseases and Stroke/Alzheimer3s Disease and
Related Disorders Association criteria (NINCDS–ADRDA) for probable
AD (McKhann et al., 1984). Patients with history of irritable bowel syn-
drome, chronic diarrhea, peptic ulcer, or gastroesophageal reﬂux dis-
ease; cardiac disease; signiﬁcant electrocardiographic abnormalities;
hematologic disorders; hepatic or renal disease; active malignancy
within 5 years; or clinically important depressive, neuropsychiatric, ce-
rebrovascular, or respiratory diseasewere excluded from this study. The
control group consisted of patients,who presented to ourmemory clinic
with subjective complaints, and underwent exactly the same diagnostic
work-up as the MCI and AD patients.
2.2. Collection of CSF
CSF sampleswere obtained from all subjects by lumbar puncture fol-
lowing an overnight fast. Spinal ﬂuid was withdrawn by experienced
physician through an atraumatic 25-gauge sprotte needle and immedi-
ately transferred to a bar code-labeled polypropylene vial and placed in
−80 °C freezer.
2.3. Biomarker analysis using multiplex xMAP (Luminex) technology
The 42 β-amyloid (Aβ1-42), T-tau and P-tau181p levels were mea-
sured in sample aliquots using the multiplex xMAP Luminex platform
(Luminex Corp, Austin, TX) with Innogenetics immunoassay kit-based
reagents (INNO-BIA AlzBio3, Ghent, Belgium). Full details of this combi-
nation immunoassay have been previously published (Vanderstichele,
2012; Reijn et al., 2007). Brieﬂy, the Innogenetics kit reagents included
well characterized capture monoclonal antibodies speciﬁc for Aβ1-42
(4D7A3), T-tau (AT120) and P-tau181p (AT270), each chemically
bonded to unique sets of color-coded beads, and analyte speciﬁc detec-
tor antibodies (HT7, 3D6). Calibration curves were produced for each
biomarker using aqueous buffered solutions that contained the1ρweighted images of control (A), medial cognitive impairment (MCI, B), and Alzheimer3s
region was observed from control to MCI to AD. No T1ρ contrast from CSF was depicted.
Table 2
Receiver operating characteristic (ROC) analysis among control, MCI and AD form T1rho
and CSF biomarkers.
Group Biomarker AUC SE Sensitivity
%
Speciﬁcity
%
95% CI p value
LB UP
Control vs
MCI
T1rho 0.65 0.09 0.60 0.77 0.49 0.82 0.09
CSF
biomarker
0.67 0.09 0.53 0.82 0.50 0.85 0.05
Control vs
AD
T1rho 0.80 0.07 0.82 0.71 0.65 0.94 0.001
CSF
biomarker
0.83 0.06 0.77 0.79 0.72 0.95 0.001
ROC = receiver operating characteristic; MCI = mild cognitive impairment; AD =
Alzheimer3s disease; CSF = cerebrospinal ﬂuid; AUC = area under curve; SE = standard
error; CI = conﬁdence interval; LB = lower bond; UP = upper bond.
Fig. 2. The error bars show themean GMandWMT1ρ values frommedial temporal lobe (MTL) in control,MCI and AD. (**) indicates the signiﬁcance difference (p b 0.05) for themean T1ρ
values between two groups.
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1948 pg/mL for recombinant tau, 27–1574 pg/mL for synthetic Aβ1-42
peptide and 8–230 pg/mL for a tau synthetic peptide phosphorylated
at the threonine 181 position (i.e. the p-tau181p standard).
2.4. MRI protocol
Written informed consent was obtained from each patient before
they underwent for MRI. Brain imaging was performed on a 1.5-Tesla
Siemens Sonata clinical-scanner (Siemens Medical Systems, Malvern,
PA, USA) using a vendor-supplied head coil. T1ρ images were acquired
using a ﬂuid-attenuated T1ρ prepared Turbo Spin-Echo pulse sequence
(Borthakur et al., 2004; 2008). The imaging parameters were: TR/TE =
2000 ms/12 ms, TSL (duration of spin lock pulse) = 10, 20, 30, 40 ms,
spin lock pulse amplitude of 500 Hz, slice thickness = 2 mm, FOV =
24 × 24 cm2, matrix size = 256 × 128, bandwidth = 130 Hz/pixel, and
echo train length=4 for a total imaging timeof 6min for four T1ρweight-
ed images. To remove the contribution from CSF to T1ρ weighted MR
signal, an inversion time (TI) of 860 ms was used. An oblique coronal
T1ρ weighted image of a slice perpendicular to the anterior/posterior
commissure (AC/PC) planewas obtained. The slice was chosen to include
the head of hippocampus. Immediately after T1ρMRI, the entire volume of
each subject3s brain was imaged in the coronal plane using a T1-weighted
3D volumetric magnetization prepared rapid acquisition gradient-echo
(MPRAGE) pulse sequence with 160 continuous slices. The parameters
were TR/TE = 3000 ms/3.5 ms, slice thickness = 1.2 mm, FOV of
240 × 240 cm2 and 192 phase encode steps, and ﬂip angle = 8° for a
total imaging time of 10 min.
2.5. Data processing
Images were transformed to a G4 PowerBook computer (Apple
Corp., Cupertino, CA) and processed with programs written in the IDL
programming language (RSI Corp., Boulder, CO). T1ρ weighted data
corresponding to different TSLs were ﬁtted pixel-wise to a mono-
exponential decay expression S(TSL) = S(0) × exp (−TSL / T1ρ)
(Borthakur et al., 2004; Borthakur et al., 2008). Pixels whose intensities
correlated poorly (R2 b 0.95) with the ﬁtting equation were set to zero.
Pixels outside of the brain were also set to zero. T1ρ values were auto-
matically calculated from gray matter (GM) and white matter (WM)
of the left and right MTL. For brain segmentation, a previously devel-
oped method was used to partition the volumetric MPRAGE scans into
92 regions of interest (ROIs) incorporating all major cortical and sub-
cortical regions (Davatzikos et al., 2008). For quantitative analysis, 4 re-
gions of interest (ROIs) were deﬁned on T1ρ images i.e. left and right
temporal lobes WM and GM. A program written in IDL was used toautomatically calculate T1ρ values only from pixels that were classiﬁed
as GM and WM located either in the left or right MTL.
2.6. Statistical analyses
For statistical analysis T1ρ values from left and right MTL were aver-
aged (separately for GM andWM). Descriptive statistics was performed
to calculate the mean value of T1ρ and CSF biomarkers for different co-
horts (controls, MCI and AD patients). Mann Whitney U-test was per-
formed to see the difference for T1ρ and CSF biomarkers between
controls, MCI and AD patients. Logistic regression with enter method
was performed to measure the prediction rate of T1ρ and CSF bio-
markers in classiﬁcation of AD, MCI and controls. Receiver operating
characteristic (ROC) analysis was performed to measure the sensitivity
and speciﬁcity. We used a default cutoff 0.5 to predict the event. Addi-
tionally, discriminant analysis using T1ρ and CSF biomarkers was
performed when three groups taken together. Pearson correlations be-
tween T1ρ versus CSF biomarkers, T1ρ versus age and between T1ρ versus
MMSE scores were also performed. p value equal or less than 0.05 was
considered statistically signiﬁcant. All the statistical computations
were performed using the Statistical Package for Social Sciences
(SPSS) version 16.0 (SPSS Inc., Chicago, USA).
3. Results
The mean MMSE scores in control (29.533 ± 1.19), MCI (25.11 ±
2.68) and AD (19.16 ± 5.57) were signiﬁcantly (p = 0.001, p b 0.001,
p = 0.002) different among groups. Mean T1ρ and CSF biomarkers
values in three groups (control, MCI and AD) are reported in Table 1.
Fig. 1 shows the overlaid T1ρ maps from MTL region (in color) on
ﬂuid-attenuated brain T1ρweighted images of control, MCI, and AD pa-
tient. Pixels with higher T1ρ (red) are more prominent in MTL of AD
Fig. 3. The scattered maps between age and T1ρ values for controls, MCI subjects and AD patients show no signiﬁcant correlations.
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brain atrophy. A lack of signal from CSF implies that the higher T1ρ
values in AD patients are not due to free ﬂuid. The error bars show
mean WM T1ρ and GM T1ρ values in controls, MCI and AD patients
(Fig. 2).
On comparative analysis, MCI subjects showed higher T1ρ, T-tau, P-tau
and lower Aβ1-42 compared to control subjects. However, only increase
in WM T1ρ (p = 0.05) reached to the statistical signiﬁcant level
(Table 1, Fig. 2). AD patients showed signiﬁcantly increased GM T1ρ
(p= 0.041), WM T1ρ (p= 0.005), T-tau (p= 0.001), P-tau (p= 0.025)
and signiﬁcantly decreased Aβ1-42 (p b 0.001) compared to controlFig. 4. The scattered maps between age and CSF biomarkers shsubjects (Table 1, Fig. 2). In AD patients, only T-tau concentrationwas sig-
niﬁcantly (p= 0.05) increased over MCI subjects.
Binary logistic regression showed that T1ρ (GMandWM)was able to
predict 77.3% controls and 40.0% MCI subjects, whereas CSF biomarkers
(T-tau, P-tau and Aβ1-42) predicted 81.8% controls and 46.7% MCI sub-
jects accurately. Combination of T1ρ and CSF biomarkers were able to
predict 86.4% controls and 66.7% MCI subjects.
T1ρ predicted 68.2% controls and 73.9% AD patients correctly while
CSF biomarkers predicted 77.3% controls and 78.3% AD patients. When
T1ρ combined with CSF biomarkers the prediction rate was 81.8% for
controls and 82.6% for AD patients.ow no signiﬁcant change in the CSF biomarkers with age.
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prediction rate was 53.3% for MCI subjects and 83.0% for AD patients
using the CSF biomarkers. Combined CSF biomarkers and T1ρ were
able to predict 57.3% MCI subjects and 84.6% AD patients.
When combined three groups together, T1ρ and CSF biomarkers
were able to classify 54.5% controls, 40% MCI subjects and 65.2% AD pa-
tients. These two biomarkers misclassiﬁed 31.8% controls as MCI sub-
jects and 13.6% controls as AD patients, while 33.3% MCI subjects were
falsely predicted as controls and 26.7% MCI subjects as AD patients.
There were false prediction of 8.7% AD patients as controls and 26.1%
AD patients as MCI subjects.
On ROC analysis, T1ρ showed greater sensitivity (60%) and less spec-
iﬁcity (77%) than CSF biomarkers (53% and 82%) in discriminating MCI
from control (Table 2). When delineating AD from control T1ρ showed
82% sensitivity and 71% speciﬁcity while CSF biomarkers showed 77%
sensitivity and 79% speciﬁcity (Table 2).
In all three cohorts, scattered maps between age and T1ρ showed no
signiﬁcant change in T1ρ values with age (Fig. 3). However, WM T1ρ in
MCI subjects and both GM T1ρ and WM T1ρ in AD patients showed an
increasing trend with age (Fig. 3). No signiﬁcant correlation of CSF bio-
markers with age and T1ρwas observed (Figs. 4–5). A negative correla-
tion trend between Aβ1-42 and T1ρ was observed in controls and MCI
subjects, while in AD patients this correlation showed a positive trend.
On the other hand, correlation between P-tau and T1ρ showed a nega-
tive trend both in MCI subjects and AD patients.Fig. 5. The scattered maps between T1ρ values and CSF biom4. Discussion
In the current study, signiﬁcantly higherWM T1ρ and GM T1ρ in MTL
in brain of AD was observed compared to that of controls, which is in
agreement with the previous studies (Haris et al., 2011; Borthakur
et al., 2008). MCI subjects showed signiﬁcantly higher WM T1ρ com-
pared to controls, which suggests that abnormality occur earlier in
WM than GM. Signiﬁcantly higher GM and WM T1ρ in AD compared
to controls imply that in AD abnormality persist both in GM and WM.
Higher changes in WM T1ρ compared to GM T1ρ suggest greater abnor-
mality in WM than GM.
Earlier, Borthakur et al., have shown decreased T1ρ with increased
plaques burden in mouse model of AD (Borthakur et al., 2006a). Over
the last two decades, a number of transgenic AD mouse models have
been created which differ in their biochemical proﬁles and disease pro-
gression rates (Elder et al., 2010; Chin, 2011). To date it is debatable
which model closely relates with the human AD pathology (Elder
et al., 2010; Chin, 2011). It is possible that themousemodel used earlier
by Borthakur et al.,may not clearly depict the humanADpathology. Fur-
ther, an explanation for higher T1ρ in the human AD patients as ob-
served in the current study and other previous studies (Haris et al.,
2011; Borthakur et al., 2008) is only due to the plaques burden is not
sufﬁcient. Moreover, in AD, hyperphosphorylation of tau protein leads
to the accumulation of neuroﬁbrillary tangles, which results in loss of
neurons. Till date no study has been performed to evaluate any relationarkers depict no signiﬁcant correlation in any group.
603M. Haris et al. / NeuroImage: Clinical 7 (2015) 598–604between phosphorylated tau protein and T1ρ in AD brain. A postmortem
studymayhelp to assess correlation between plaques burden, biochem-
ical changes and T1ρ relaxation time in the human brain, and may pro-
vide a more precise explanation for increased T1ρ values in the human
AD patients.
Majority of studies have reported decreased Aβ1-42, and increased
T-tau and P-tau levels in CSF of MCI and AD patients (Hansson et al.,
2006; Mattsson et al., 2009; Andreasen et al., 2001, 2003) and our
ﬁndings are in conformity with those studies. It is widely believed that
increased CSF T-tau level reﬂects neuronal and axonal damage. Howev-
er, clinical studies have shown that the elevated CSF T-tau level is not
speciﬁc to AD as it may also be elevated in other neurodegenerative dis-
eases (Arai et al., 1997; Urakami et al., 2001). In a recent study, Hampel3s
group reported that when compared with T-tau, P-tau showed better
speciﬁcity for AD (Hampel, and Blennow, 2004). It has also been
shown that the P-tau3s level consistently elevated in AD when com-
pared with frontotemporal dementia (FTD), lewy body dementia
(LBD), and control (Parnetti et al., 2001). An adequate explanation for
decreased concentration of Aβ1-42 in CSF of AD patients is still lacking.
The suggested explanation that it is due to accumulation of Aβ1-42 in
plaques is not sufﬁcient, as decreased Aβ1-42 concentration in CSF of
patients with Creutzfeldt–Jakob disease without apparent plaque for-
mation has been reported previously (Wiltfang et al., 2003; Otto et al.,
2000).Moreover, considerable uncertainty exists with respect to the in-
ﬂuence of ageing on CSF biomarkers levels (de Leon et al., 2004;
Hulstaert et al., 1999). Normal ageing studies have depicted both posi-
tive and negative age effects (Andreasen et al., 2001; de Leon et al.,
2004; Hulstaert et al., 1999). In the current study, no age related chang-
es in CSF biomarkers were observed.
Medial temporal lobe (MTA) atrophy as observed on MRI is consid-
ered to be an early and sensitive marker for AD, and is assumed that it
reﬂects underlying neuronal loss in hippocampus and temporal lobe
(Clerx et al., 2013; Jack et al., 1997; Duara et al., 2008). However, MTA
may also be present in other types of dementia (Tam et al., 2005;
Barber et al., 1999) and absence of MTA does not exclude the diagnosis
of AD especially in the early stage. Studies have been performed to in-
vestigate the cross-sectional relation between CSF biomarkers and atro-
phy onMRI. Some observed no relation between CSF tau or Aβ1-42 and
whole-brain atrophy (Sluimer et al., 2010), while others found a signif-
icant inverse relationship between CSF P-tau and hippocampal volume
in MCI (Herukka et al., 2008). It has been shown that the increased
CSF tau level corresponds to the higher baseline hippocampal volume
in AD. The same study has also reported, no signiﬁcant effect of T-tau
level on hippocampal atrophy (Hampel et al., 2005).
In the current study, none of CSF biomarkers were signiﬁcantly
change in MCI compared to controls, while WM T1ρ in MCI was signiﬁ-
cantly higher than controls. Even if T1ρwas signiﬁcantly higher inMCI it
did not appear as a good predictor of MCI. T1ρ in combination with CSF
biomarkers improved the prediction rate for MCI (66.7%). Similarly,
combined T1ρ and CSF biomarkers showed better prediction rate for
control (81.2%) and AD (82.6%) compared to either T1ρ or CSF bio-
markers alone. Combined T1ρ and CSF biomarkers were able to discrim-
inate 57.3% MCI and 84.6% AD. A longitudinal study is needed to
elucidate the combined clinical utility of these two biomarkers in pro-
gression from MCI to AD.
In the current study, no correlation between T1ρ and CSF biomarkers
suggests that these two biomarkers are independent to each other and
have differential diagnostic efﬁcacy. Longitudinal studies are needed
to understand the relationship between T1ρ and CSF biomarkers. No cor-
relation between T1ρ and age was observed which suggests that the in-
creased T1ρ is due to changes in underlying pathology instead of any age
related changes.
No correlation between T1ρ and MMSE suggests that the functional
changes asmeasured by T1ρ probably do not exclusively reﬂect the cog-
nitive impairment. Moreover, the cognitive analysis depends on the
patient3s behavior which could ﬂuctuate with time. A test retest studycan be performed to evaluate covariance in the measurement of the
MMSE score. On the other hand CSF biomarker analysis reﬂects the bio-
chemical changes in the CSF not in the actual pathological tissues. The
direct measurement of the biochemical changes in the brain tissues as-
sociated with the cognitive performance might be better correlated
with the MMSE score.
Recently,Watts et al., have evaluated the age dependence changes in
GM andWM T1ρ relaxation times in brain of normal human volunteers
on a 3-TMRI scanner (Watts et al., 2014). They have observed a positive
correlation betweenWMT1ρ and agewhile theGMT1ρ showednegative
correlation with age. In the current study, both WM T1ρ and GM T1ρ
showed no signiﬁcant correlation with age. This may be due to the
fact that in previous study normal subjects with larger range of age
have been studied compared to the current study. However, in this
study, both WM T1ρ and GM T1ρ in AD and WM T1ρ in MCI showed an
increasing trendwith age. This may be due to the higher AD related pa-
thology changeswith increasing age. In addition,Watts et al. have found
~7–10% lower T1ρ value both in GM and WM compared to the current
study. This is due to the reason that previous study has used 3 T MRI,
while the current study used 1.5 T MRI, and it is well known fact that
with higher ﬁeld strength T1ρ decreases (Singh et al., 2014).
One of the limitation of the current study is the cross-sectional de-
sign, inwhich the values of two different diagnosticmethodswere com-
pared in subject with the clinical diagnosis as gold standard. Further,
longitudinal study with larger sample size is needed to properly assess
the relative value of thesemarkers in tracking changes along the clinical
continuum of AD. In conclusion, both CSF biomarkers and T1ρMRI seem
to have incremental value in diagnosis of AD. By applying them together
diagnostic accuracy might be increased.
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